

Alere™ Technical Specification *Urine Analysis*

Urine Analysis

Drug/Metabolite	UKAS ISO 17025:2005 Accreditation (Y/N) *	Method	Analytical Cut-off Urine (ng/mL) **	Estimated Uncertainty of Measurement (±%)	Experimental Bias Measurement Urine Matrix
Benzodiazepine Group					
Desmethyldiazepam	Y	LC-MS/MS	200	8	0
Diazepam	Y	LC-MS/MS	200	8	0
Lorazepam	Y	LC-MS/MS	200	14	+7
Oxazepam	Y	LC-MS/MS	200	9	-1
Temazepam	Y	LC-MS/MS	200	10	-2
Buprenorphine Group					
Buprenorphine	Y	LC-MS/MS	2	13	+30
Norbuprenorphine	Y	LC-MS/MS	2	14	+2
Cannabis Group					
11 nor-delta-9-THC carboxylic acid	Y	LC-MS/MS	15	13	+5
Cocaine Group					
Benzoylcegonine	Y	LC-MS/MS	150	14	+5
Ketamine Group					
Ketamine	N	LC-MS/MS	25	8	+16
LSD Group					
LSD	Y	LC-MS/MS	0.3	15	+9
Methadone Group					
Methadone	Y	LC-MS/MS	300	8	-1
Methadone metabolite (EDDP)	Y	LC-MS/MS	300	7	+4
Methaqualone					
Methaqualone	Y	LC-MS/MS	300	14	+7
Opiate Group					
6-monoacetylmorphine (6-MAM)	Y	LC-MS/MS	10	8	+6
Codeine	Y	LC-MS/MS	300	9	+6
Dihydrocodeine	Y	LC-MS/MS	300	10	+6
Morphine	Y	LC-MS/MS	300	12	+3
Phencyclidine (PCP)					
PCP	Y	LC-MS/MS	25	13	+16
Propoxyphene					
Propoxyphene	Y	LC-MS/MS	300	11	0
Tramadol					
Tramadol	Y	LC-MS/MS	100	18	+17
Additional Tests General Screen and Identification					
General Screen and Identification e.g. Cathinone, Mephedrone	N	LC-MS	N/A	N/A	N/A
Diuretics	Y	LC-MS	250	N/A	N/A

* The analytes indicated as 'N' do not form part of our UKAS ISO 17025:2005 Schedule of Accreditation; however, they are subject to the same quality assurance controls and acceptance criteria as the accredited analytes.

** Cut-off levels shown are standard. However these can be set to specific customer requirements upon request.